These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35906180)

  • 1. SGLT2 Inhibitors-A Medical Revelation: Molecular Signaling of Canagliflozin Underlying Hypertension and Vascular Remodeling.
    Yagi T; Kolluru GK
    J Am Heart Assoc; 2022 Aug; 11(15):e026774. PubMed ID: 35906180
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW
    Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nocturnal hypertension in diabetes: Potential target of sodium/glucose cotransporter 2 (SGLT2) inhibition.
    Kario K; Weber M; Ferrannini E
    J Clin Hypertens (Greenwich); 2018 Mar; 20(3):424-428. PubMed ID: 29457344
    [No Abstract]   [Full Text] [Related]  

  • 4. Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension.
    Bloch MJ
    J Am Soc Hypertens; 2016 Mar; 10(3):186-7. PubMed ID: 27408945
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.
    Pfeifer M; Townsend RR; Davies MJ; Vijapurkar U; Ren J
    Cardiovasc Diabetol; 2017 Feb; 16(1):29. PubMed ID: 28241822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canagliflozin and cardiovascular outcomes in Type 2 diabetes.
    Sarraju A; Spencer-Bonilla G; Rodriguez F; Mahaffey KW
    Future Cardiol; 2021 Jan; 17(1):39-48. PubMed ID: 32748638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose cotransporter 2 inhibitors for macroalbuminuria: A new indication.
    Bloomgarden Z; Handelsman Y
    J Diabetes; 2020 Jan; 12(1):8-9. PubMed ID: 31722441
    [No Abstract]   [Full Text] [Related]  

  • 9. Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors.
    Wilcox CS
    Hypertension; 2020 Apr; 75(4):894-901. PubMed ID: 32114848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D; Javor E; Lucijanić T; Skelin M
    Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT-2 inhibitors in diabetes: a focus on renoprotection.
    Gonzalez DE; Foresto RD; Ribeiro AB
    Rev Assoc Med Bras (1992); 2020 Jan; 66Suppl 1(Suppl 1):s17-s24. PubMed ID: 31939531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
    Chrysavgis L; Papatheodoridi AM; Chatzigeorgiou A; Cholongitas E
    J Gastroenterol Hepatol; 2021 Apr; 36(4):893-909. PubMed ID: 33439540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose cotransporter 2 inhibitors for treating diabetes mellitus.
    Goldberg N; Fralick M
    CMAJ; 2017 May; 189(20):E724. PubMed ID: 28536128
    [No Abstract]   [Full Text] [Related]  

  • 14. Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS.
    Vallon V; Thomson SC
    Nat Rev Nephrol; 2017 Sep; 13(9):517-518. PubMed ID: 28781373
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
    Lupsa BC; Inzucchi SE
    Diabetologia; 2018 Oct; 61(10):2118-2125. PubMed ID: 30132031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose cotransporter 2 inhibitors for the management of type 2 diabetes.
    Siamashvili M; Davis SN
    Expert Opin Pharmacother; 2021 Nov; 22(16):2181-2198. PubMed ID: 34388350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: The SHIFT-J study.
    Kario K; Hoshide S; Okawara Y; Tomitani N; Yamauchi K; Ohbayashi H; Itabashi N; Matsumoto Y; Kanegae H
    J Clin Hypertens (Greenwich); 2018 Oct; 20(10):1527-1535. PubMed ID: 30246286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.
    Dandona P; Chaudhuri A
    Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28440009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
    Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K;
    Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
    Handelsman Y
    Endocr Pract; 2015 Sep; 21(9):1054-65. PubMed ID: 26132997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.